Quarterly guidance

Quarterly guidance
No quarterly guidance was given.

Annual guidance

Revenue growth
15% to 25%
Cost of sales
$1.7 billion
R&D expenses
$2.7 billion
SG&A expenses
Approximately $1 billion
Capital expenditure
$200 million
Year-end cash and investments
$8.1 billion to $8.3 billion

Outlook

Commercial growth
Expects continued growth driven by mNEXSPIKE and international partnerships.
Oncology pipeline
Advancing intismeran across multiple tumor types and stages.
Financial discipline
Maintaining focus on reducing cash costs and optimizing R&D spend.
Respiratory portfolio
Pursuing additional regulatory approvals globally for flu and COVID vaccines.
Norovirus
Engaging with health authorities to determine next steps for the program.